Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Trevi Therapeutics, Inc. | trvi-ex322_207.htm |
| EX-32.1 - EX-32.1 - Trevi Therapeutics, Inc. | trvi-ex321_206.htm |
| EX-31.2 - EX-31.2 - Trevi Therapeutics, Inc. | trvi-ex312_205.htm |
| EX-31.1 - EX-31.1 - Trevi Therapeutics, Inc. | trvi-ex311_204.htm |
| EX-10.10 - EX-10.10 - Trevi Therapeutics, Inc. | trvi-ex1010_255.htm |
| EX-4.2 - EX-4.2 - Trevi Therapeutics, Inc. | trvi-ex42_203.htm |
| 10-K - 10-K - Trevi Therapeutics, Inc. | trvi-10k_20191231.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the Registration Statement (Form S-8 No. 333-231260) pertaining to the 2012 Stock Incentive Plan, as amended, the 2019 Stock Incentive Plan, and the 2019 Employee Stock Purchase Plan of Trevi Therapeutics, Inc. of our report dated March 16, 2020, with respect to the consolidated financial statements of Trevi Therapeutics, Inc. included in this Annual Report (Form 10-K) for the year ended December 31, 2019.
/s/ Ernst & Young LLP
Stamford, Connecticut
March 16, 2020